NCT06630247 is a Phase 1 clinical trial of XL495 in Solid Cancers, sponsored by Exelixis.

Who is sponsoring NCT06630247?

NCT06630247 is sponsored by Exelixis.

What drugs are being tested in NCT06630247?

Interventions in NCT06630247: XL495, ADC cytotoxic agents.

What condition does NCT06630247 study?

NCT06630247 studies Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer), Metastatic Solid Tumor, Locally Advanced Solid Tumor, Urothelial Cancer of Renal Pelvis.

Is NCT06630247 still recruiting?

NCT06630247 is currently terminated. Last updated 25 June 2025.

Last reviewed 2025-06-25 · How we verify

NCT06630247

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Terminated Phase 1 Last updated 25 June 2025

What this trial tests

Phase 1 trial testing XL495 in Solid Cancers in 9 participants. Terminated before completion.

Timeline

17 October 2024

Primary endpoint
7 May 2025

7 May 2025

Quick facts

Lead sponsor	Exelixis
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	17 October 2024
Primary completion	7 May 2025
Estimated completion	7 May 2025
Sites	10 locations across United States

Drugs / interventions tested

XL495 — full drug profile →
ADC cytotoxic agents — full drug profile →

Conditions studied

Solid Cancers — all drugs for Solid Cancers →
Solid Tumor Cancer — all drugs for Solid Tumor Cancer →
Solid Tumor Malignancy — all drugs for Solid Tumor Malignancy →
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) — all drugs for Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) →

Sponsor

Exelixis — full company profile →

Who can join

18 and older, any sex, with Solid Cancers or Solid Tumor Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Solid Cancers

Currently open trials in the same condition.

NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
NCT07479667 — An Antibody-armored Dendritic Cell in Patients With Solid Tumors · Phase 1 · recruiting
NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07167381 — xDRIVE for Florida-based Cancer Patients · NA · recruiting
NCT07058948 — Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors · Phase 2 · recruiting

Other Exelixis trials

Trials by the same sponsor.

NCT06545331 — Study of XB010 in Subjects With Solid Tumors · Phase 1 · recruiting
NCT05932862 — A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors · Phase 1 · recruiting
NCT06191796 — Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Re · Phase 1 · terminated
NCT05144347 — Study of XL114 in Subjects With Non-Hodgkin's Lymphoma · Phase 1 · terminated
NCT05176483 — Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06630247 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Exelixis
Last refreshed: 25 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06630247.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing